ERB-196 is primarily utilized in the field of medical research, particularly in the study of cancer therapies. It functions as a selective estrogen receptor beta (ERβ) agonist, which makes it valuable for investigating the role of ERβ in various physiological and pathological processes. Researchers employ ERB-196 to explore its potential in treating hormone-dependent cancers, such as breast and prostate cancer, by targeting estrogen receptor pathways. Additionally, it is used in preclinical studies to understand its effects on inflammation, neuroprotection, and metabolic regulation, offering insights into its therapeutic applications beyond oncology. Its specificity for ERβ allows for a focused examination of receptor-mediated mechanisms, aiding in the development of targeted treatments.